Metropolis Healthcare Launches Centre of Genomics to Scale Precision Diagnostics

Metropolis Healthcare Limited has announced the launch of its Centre of Genomics, marking a major milestone in expanding its advanced genomics, molecular diagnostics, and precision medicine capabilities. The initiative strengthens Metropolis’ position in delivering clinically actionable genomic insights across multiple medical specialities.

Building on a Strong Genomics Foundation

Over the years, Metropolis has developed deep expertise in advanced genomics, with a strong focus on precision oncology anchored at its Global Reference Laboratory in Mumbai. 

This foundation has been further enhanced through the integration of Core Diagnostics’ specialised genomics laboratory in the Delhi NCR region. Together, these facilities now function as CAP-accredited national referral laboratories, forming the core operational backbone of the Centre of Genomics.

Integrated Capabilities and Advanced Technology

The Centre of Genomics unifies a comprehensive portfolio of next-generation sequencing (NGS)-based assays, robust bioinformatics platforms, and high-level scientific interpretation capabilities. To further strengthen its technology infrastructure, Metropolis has deployed Illumina’s NovaSeq™ X Series for research purposes. 

Powered by Illumina’s XLEAP-SBS™ chemistry, the system delivers exceptional throughput, accuracy, and sustainability, enabling the sequencing of over 20,000 whole genomes annually, more than double the capacity of earlier-generation sequencers.

Beyond the NovaSeq™ X Series, the Centre is supported by a multi-platform NGS infrastructure already operational across Metropolis’ key genomics hubs, ensuring scalability and operational resilience.

Expert Teams Driving Clinical Impact

The Centre of Genomics brings together multidisciplinary teams comprising molecular pathologists, genomic scientists, bioinformaticians, researchers, and certified genetic counsellors. This collaborative approach ensures complex genomic data is translated into reliable, clinically meaningful insights that directly support patient care and treatment decisions.

Platform for Innovation and Global Collaboration

Beyond expanding its test portfolio, the Centre of Genomics is designed as a platform for continuous test development, AI-enabled analytics, and deeper digital integration. With active B2B operations across multiple countries and engagement in pharmaceutical programs and clinical trials, Metropolis is positioning the Centre as a strategic partner for global research, companion diagnostics, and precision-led drug development.

Also Read: Metropolis Healthcare Q2 Profit Up 13%!

Conclusion

The launch of the Centre of Genomics underscores Metropolis Healthcare’s commitment to advancing precision medicine and genomic science. By integrating cutting-edge technology, expert talent, and scalable infrastructure, Metropolis is well-positioned to deliver transformative genomic solutions that enhance clinical outcomes and support the future of personalised healthcare.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.